The Good, The Bad, And The Uncertain: Trump’s Second Administration And The Rx Industry

The pharma industry arguably suffered none of the downside risks that were possible during the first Trump administration, and their relationship with Biden could not have gone much worse. And while they may hope a Trump return could help their fortunes, having RFK Jr. supervising the FDA is likely not the prescription they want.

With Trump’s return, pharma trades a disagreeable White House for an unpredictable one (Shutterstock)

More from Outlook

More from Global Vision